WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has named Vimal Patel, PharmD, as senior vice president of medical affairs, adding a seasoned dermatology and immunology executive as the company advances its pipeline of rare skin disease therapies.
Patel brings more than 25 years of medical affairs leadership experience spanning late-stage development, commercial launches, and lifecycle management. His background includes work on high-profile dermatology and immunology therapies such as OPZELURA®, povorcitinib, ILUMYA®, ODOMZO®, REMICADE®, and STELARA®.
At Palvella, Patel will lead the company’s medical affairs organization, with responsibility for scientific engagement, collaboration with key opinion leaders, disease state awareness, and medical education. His role will focus on supporting Palvella’s QTORIN™ programs, which target serious and rare skin conditions, including microcystic lymphatic malformations and cutaneous venous malformations.
Founder and Chief Executive Officer Wes Kaupinen said Patel’s appointment comes at a pivotal moment as the company prepares for potential near-term launches. He said Patel’s experience building medical affairs teams and guiding products through late-stage development will be critical as Palvella expands its rare disease pipeline.
Before joining Palvella, Patel served as dermatology therapeutic area head for medical affairs at Incyte, where he led medical strategy across atopic dermatitis, vitiligo, and hidradenitis suppurativa. In that role, he oversaw evidence generation, medical education, medical insights, and field medical execution, and played a key role in the advancement of OPZELURA® and povorcitinib. He previously held senior leadership positions at Sun Pharma, including head of medical sales liaisons and medical information for North America, as well as global commercialization lead for ODOMZO®.
Earlier in his career, Patel spent nearly 15 years at Johnson & Johnson in a range of medical affairs and brand strategy roles, contributing to the success of major immunology and dermatology products such as REMICADE® and STELARA®. He holds a Bachelor of Science degree and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy.
Patel said Palvella’s focus on serious, underserved rare skin diseases drew him to the role. He pointed to the lack of FDA-approved treatment options for many of these conditions and said advancing rigorous science and strong clinical evidence will be central to improving patient outcomes. He described QTORIN™ as a platform with the potential to reshape treatment approaches by targeting the underlying biology of rare skin diseases, adding that he is eager to support the development and possible launch of the company’s programs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.